Reversion of the malignant phenotype of gastric cancer cell SGC7901 by c-erbB-2-specific hammerhead ribozyme

Cancer Gene Ther. 2001 Nov;8(11):835-42. doi: 10.1038/sj.cgt.7700372.

Abstract

The c-erbB-2/neu-encoded protein p185 is closely related to the growth and metastasis of adenocarcinoma. We sought to reverse the malignant phenotype of gastric cancer cell line SGC7901 with c-erbB-2-specific ribozyme. We designed the ribozyme and generated the in vitro transcription vectors of the ribozyme and its substrate. In vitro cleavage reaction indicated that the ribozyme catalyzed 79.3% target RNA in 1 hour at 37 degrees C. Then, we generated the eucaryotic expression vectors of the ribozyme and transfected them into SGC7901 cells, which highly express p185. Analyses showed that the c-erbB-2 mRNA and p185 were reduced remarkably in the ribozyme-transfected cells. The growth rate of the ribozyme-transfected cells was much lower than that of the control group. Tumorigenicity was also decreased dramatically in nude mice. The results demonstrated that c-erbB-2-specific ribozyme may inhibit the malignancy of gastric cancer cells SGC7901.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / genetics
  • Adenocarcinoma / pathology
  • Adenocarcinoma / therapy*
  • Animals
  • Base Sequence
  • Female
  • Genes, erbB-2 / genetics*
  • Genetic Therapy
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Molecular Sequence Data
  • Phenotype
  • Plasmids
  • RNA, Antisense / therapeutic use*
  • RNA, Catalytic / genetics
  • RNA, Catalytic / therapeutic use*
  • RNA, Messenger / antagonists & inhibitors
  • RNA, Messenger / metabolism
  • Stomach Neoplasms / genetics
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / therapy*
  • Transfection
  • Tumor Cells, Cultured

Substances

  • RNA, Antisense
  • RNA, Catalytic
  • RNA, Messenger
  • hammerhead ribozyme